Loading clinical trials...
Loading clinical trials...
Interpretable Prediction of Pancreatic Neoplasms in Chronic Pancreatitis Patients With Focal Pancreatic Lesions Based on XGBoost Machine Learning and SHAP
This study aims to develop XGBoost machine learning model to predict pancreatic neoplasms in CP patients with focal pancreatic lesions.
Pancreatic neoplasms include various types, with pancreatic cancer being the most common and having a poor prognosis. Chronic pancreatitis (CP) can progress to pancreatic cancer, and detecting neoplasms in CP patients is challenging due to similar imaging and clinical presentations. Current diagnostic methods like CT and tumor markers have limitations, and endoscopic ultrasound-guided tissue acquisition has moderate sensitivity. Machine learning (ML) shows promise in medical fields, but its "black box" nature limits its application. SHapley additive exPlanations (SHAP) can provide intuitive explanations for ML models. This study aims to develop an ML model to predict pancreatic neoplasms in CP patients with focal pancreatic lesions and use SHAP to explain the model, aiding future research.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Changhai Hospital
Shanghai, Shanghai Municipality, China
Start Date
July 1, 2025
Primary Completion Date
August 1, 2025
Completion Date
August 5, 2025
Last Updated
September 30, 2025
113
ACTUAL participants
XGBoost machine learning
DIAGNOSTIC_TEST
Lead Sponsor
Changhai Hospital
NCT06051695
NCT06885697
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions